RESEARCH TRIANGLE PARK, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 14, 2025, at 6:00 p.m. ET.
Link to the live audio webcast and replay of the presentation may be accessed in the Investors & Media section of BioCryst’s website at www.biocryst.com.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on LinkedIn.
BCRXW
Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com


Đề xuất
PHONO Marks 20th Anniversary and Secures New Orders at RE+ 2026
A Seattle Startup Brings Your Pet to Life on Your Phone and Laptop With the Avatar Mirroring Their Every Move in Real Time
HEARTBOT AI Wins Chunghwa Telecom Special Award at Meet Neo Star 2026
Allooloo Tops 100M Capital Markets AI Agent Traffic a Month
KONST Showcases “24/7 GPUs Delivered in Asia” at SC26, Offering AI Compute Services from Validation and Delivery to Round-the-Clock Operations
APEC CEO Summit 2026 Concludes Successfully in Shenzhen